PL2110126T3 - Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej - Google Patents
Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnejInfo
- Publication number
- PL2110126T3 PL2110126T3 PL08007640T PL08007640T PL2110126T3 PL 2110126 T3 PL2110126 T3 PL 2110126T3 PL 08007640 T PL08007640 T PL 08007640T PL 08007640 T PL08007640 T PL 08007640T PL 2110126 T3 PL2110126 T3 PL 2110126T3
- Authority
- PL
- Poland
- Prior art keywords
- active ingredient
- liquid
- fluorised
- instillative
- inhalative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08007640A EP2110126B9 (de) | 2008-04-18 | 2008-04-18 | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2110126T3 true PL2110126T3 (pl) | 2012-04-30 |
Family
ID=39708796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08007640T PL2110126T3 (pl) | 2008-04-18 | 2008-04-18 | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8986738B2 (pl) |
| EP (1) | EP2110126B9 (pl) |
| JP (1) | JP4990929B2 (pl) |
| CN (1) | CN101559229B (pl) |
| AT (1) | ATE532505T1 (pl) |
| AU (1) | AU2009201137A1 (pl) |
| BR (1) | BRPI0900767A2 (pl) |
| CA (1) | CA2662943A1 (pl) |
| DK (1) | DK2110126T3 (pl) |
| ES (1) | ES2377152T3 (pl) |
| MX (1) | MX2009003812A (pl) |
| PL (1) | PL2110126T3 (pl) |
| PT (1) | PT2110126E (pl) |
| TW (1) | TWI417108B (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| EP2332525A1 (en) * | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| WO2012093113A1 (en) | 2011-01-04 | 2012-07-12 | Novaliq Gmbh | O/w-emulsions comprising semifluorinated alkanes |
| ES2617968T3 (es) | 2011-05-25 | 2017-06-20 | Novaliq Gmbh | Composición farmacéutica para la administración a uñas |
| ES2962524T3 (es) | 2011-05-25 | 2024-03-19 | Dermaliq Therapeutics Inc | Composición farmacéutica tópica a base de alcanos semifluorados |
| DK2806886T3 (en) * | 2012-01-23 | 2017-06-06 | Novaliq Gmbh | STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES |
| NZ701073A (en) * | 2012-04-23 | 2016-04-29 | Chiesi Farma Spa | Method and system for the administration of a pulmonary surfactant by atomization |
| TR201812013T4 (tr) | 2012-09-12 | 2018-09-21 | Novaliq Gmbh | Göz yikama bi̇leşi̇mleri̇. |
| CN113679699B (zh) | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| BR122019024319B1 (pt) | 2012-09-12 | 2022-09-27 | Novaliq Gmbh | Uso de composições de alcano semifluorado na fabricação de um medicamento para o tratamento de uma condição associada com queratoconjuntivite seca |
| BR112016001522B1 (pt) | 2013-07-23 | 2019-10-01 | Novaliq Gmbh | Composições de anticorpo estabilizado |
| US11648261B2 (en) * | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US10925889B2 (en) * | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| KR102584063B1 (ko) | 2015-09-30 | 2023-09-27 | 노바리크 게엠베하 | 부분불소화 화합물 |
| DK3355990T3 (da) | 2015-09-30 | 2019-09-16 | Novaliq Gmbh | Semifluorinerede forbindelser og disses sammensætninger |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| AU2017329772B2 (en) | 2016-09-22 | 2023-02-02 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| MX2019003364A (es) | 2016-09-23 | 2019-10-02 | Novaliq Gmbh | Composiciones oftalmicas que comprenden ciclosporina. |
| CA3045743C (en) | 2016-12-23 | 2023-08-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| MX388460B (es) | 2017-04-21 | 2025-03-20 | Dermaliq Therapeutics Inc | Composiciones de yodo. |
| WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
| WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN119909046A (zh) | 2017-10-04 | 2025-05-02 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| MX2020009132A (es) | 2018-03-02 | 2020-12-11 | Novaliq Gmbh | Composiciones farmaceuticas que comprenden nebivolol. |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| WO2020064556A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Topical sunscreen formulation |
| AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| US12226478B2 (en) | 2019-04-28 | 2025-02-18 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| AU2020340561B2 (en) | 2019-09-06 | 2026-01-22 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| DE102021005494A1 (de) | 2021-11-06 | 2023-05-11 | Kocher-Plastik Maschinenbau Gmbh | Trennvorrichtung |
| DE102021005495A1 (de) | 2021-11-06 | 2023-05-11 | Kocher-Plastik Maschinenbau Gmbh | Trennvorrichtung |
| CN121218978A (zh) | 2023-04-03 | 2025-12-26 | 德马利克治疗公司 | 三唑类抗真菌药组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5869539A (en) * | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US6585957B1 (en) * | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| CA2563544A1 (en) * | 2004-04-19 | 2005-10-27 | Centre National De La Recherche Scientifique (C.N.R.S.) | Lung surfactant supplements |
| DE102005055811A1 (de) * | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
-
2008
- 2008-04-18 PL PL08007640T patent/PL2110126T3/pl unknown
- 2008-04-18 AT AT08007640T patent/ATE532505T1/de active
- 2008-04-18 DK DK08007640.9T patent/DK2110126T3/da active
- 2008-04-18 EP EP08007640A patent/EP2110126B9/de active Active
- 2008-04-18 ES ES08007640T patent/ES2377152T3/es active Active
- 2008-04-18 PT PT08007640T patent/PT2110126E/pt unknown
-
2009
- 2009-03-20 AU AU2009201137A patent/AU2009201137A1/en not_active Abandoned
- 2009-03-27 TW TW098110222A patent/TWI417108B/zh not_active IP Right Cessation
- 2009-03-31 US US12/415,482 patent/US8986738B2/en active Active
- 2009-04-08 MX MX2009003812A patent/MX2009003812A/es active IP Right Grant
- 2009-04-14 BR BRPI0900767-9A patent/BRPI0900767A2/pt not_active IP Right Cessation
- 2009-04-16 CA CA002662943A patent/CA2662943A1/en not_active Abandoned
- 2009-04-17 JP JP2009101019A patent/JP4990929B2/ja active Active
- 2009-04-20 CN CN2009101310362A patent/CN101559229B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009201137A1 (en) | 2009-11-05 |
| ES2377152T3 (es) | 2012-03-22 |
| DK2110126T3 (da) | 2012-02-27 |
| ES2377152T9 (es) | 2013-02-18 |
| TW200950809A (en) | 2009-12-16 |
| EP2110126B1 (de) | 2011-11-09 |
| EP2110126B9 (de) | 2012-09-19 |
| ATE532505T1 (de) | 2011-11-15 |
| CN101559229A (zh) | 2009-10-21 |
| CA2662943A1 (en) | 2009-10-18 |
| EP2110126A1 (de) | 2009-10-21 |
| PT2110126E (pt) | 2012-02-20 |
| CN101559229B (zh) | 2013-07-31 |
| US20100008996A1 (en) | 2010-01-14 |
| JP2009256353A (ja) | 2009-11-05 |
| MX2009003812A (es) | 2009-10-19 |
| US8986738B2 (en) | 2015-03-24 |
| BRPI0900767A2 (pt) | 2010-12-28 |
| JP4990929B2 (ja) | 2012-08-01 |
| TWI417108B (zh) | 2013-12-01 |
| HK1135043A1 (en) | 2010-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2110126T3 (pl) | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej | |
| Wang et al. | S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway | |
| JP5271918B2 (ja) | メタボリック症候群治療用の新規組成物 | |
| ES2547336T3 (es) | Composición tópica para su uso para el tratamiento de enrojecimiento inducido por rosácea | |
| AU2012262534B2 (en) | Method of determining vasoreactivity using inhaled nitric oxide | |
| PE20121396A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol | |
| ATE489048T1 (de) | Vorrichtung für kombinierte behandlung | |
| WO2009097443A3 (en) | Liquid formulations of compounds active at sulfonylurea receptors | |
| MX2009000507A (es) | Espuma farmaceutica de acidos grasos. | |
| WO2008007322A3 (en) | Anti-hemorrhage medication pack | |
| PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| UY31406A1 (es) | "producto de dispersion solida que contiene un compuesto a base de n-aril urea". | |
| AR070842A1 (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 | |
| EP2397142A3 (en) | Use of dpp iv inhibitors | |
| JP2023510661A (ja) | 窒素酸化物を生成するための方法及び組成物、並びにそれらの使用 | |
| ATE527976T1 (de) | Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes | |
| AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
| JPWO2010103844A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
| De Moura et al. | The role of bradykinin, AT2 and angiotensin 1–7 receptors in the EDRF‐dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat | |
| EP4138795A1 (en) | Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2 | |
| ECSP24020925A (es) | Profármaco de derivados de pirrolidona como activador de glucocinasa | |
| Chiruvella et al. | Intraperitoneal instillation of ropivacaine plus dexmedetomidine for pain relief after laparoscopic hysterectomy: A comparison with ropivacaine alone | |
| Fike et al. | Cyclooxygenase contracting factors and altered pulmonary vascular responses in chronically hypoxic newborn pigs | |
| Fröhlich et al. | Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test | |
| Dani et al. | Toxicity of corticosteroids and catecholamines for mice neuronal cell cultures: Role of preservatives |